menu
    • menu

    Company profile for Tubulis

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for p...
    Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TubulisGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Butenandtstraße 1, 81375 München
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://tubulis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tubulis Announces Closing of Series C, Total Raised to €344M
    Tubulis Announces Closing of Series C, Total Raised to €344M

    30 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251030732465/en/Tubulis-Announces-Second-Closing-of-Series-C-Bringing-Total-Raised-to-%E2%82%AC344M-US-%24401M

    BUSINESSWIRE
    30 Oct 2025
    Share Share
    Tubulis Unveils Initial Phase I/IIa Data For TUB-040 at ESMO
    Tubulis Unveils Initial Phase I/IIa Data For TUB-040 at ESMO

    19 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251019763236/en/Tubulis-Presents-First-Clinical-Data-from-Phase-IIIa-Trial-for-TUB-040-in-Platinum-Resistant-Ovarian-Cancer-PROC-at-ESMO-2025

    BUSINESSWIRE
    19 Oct 2025
    Share Share
    ESMO: Tubulis' Next-Gen ADC Lives Up To Hype With 59% ORR
    ESMO: Tubulis' Next-Gen ADC Lives Up To Hype With 59% ORR

    19 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/esmo-tubulis-next-gen-adc-posts-59-response-rate-justifying-investor-interest

    FIERCE BIOTECH
    19 Oct 2025
    Share Share
    Tubulis Touts $361M Series C As Next-Gen ADC Data Drop Nears
    Tubulis Touts $361M Series C As Next-Gen ADC Data Drop Nears

    15 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/tubulis-nets-361m-financing-round-next-gen-adc-data-drop-nears

    FIERCE BIOTECH
    15 Oct 2025
    Share Share
    Tubulis Raises €308M Series C To Advance TUB-040 ADC And Pipeline
    Tubulis Raises €308M Series C To Advance TUB-040 ADC And Pipeline

    15 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-15/tubulis-raises-308-million-series-c-to-accelerate-clinical-development-of-lead-adc-candidate-tub-04

    PHARMIWEB
    15 Oct 2025
    Share Share
    Tubulis Unveils Ph I/IIa Data in Ovarian Cancer at ESMO 2025
    Tubulis Unveils Ph I/IIa Data in Ovarian Cancer at ESMO 2025

    22 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250919911627/en/Tubulis-to-Present-First-Phase-IIIa-Trial-Data-for-ADC-Candidate-TUB-040-in-Platinum-Resistant-Ovarian-Cancer-in-Late-Breaking-Oral-Presentation-at-ESMO-2025

    BUSINESSWIRE
    22 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search